Stratec Biomedical AG (ETR:SBS) has been assigned a consensus rating of “Hold” from the six research firms that are currently covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is €60.50 ($70.35).

SBS has been the subject of several research reports. Kepler Capital Markets set a €66.00 ($76.74) target price on Stratec Biomedical AG and gave the stock a “buy” rating in a report on Wednesday, July 26th. Warburg Research set a €62.00 ($72.09) target price on Stratec Biomedical AG and gave the stock a “buy” rating in a report on Tuesday, July 25th. Berenberg Bank set a €59.00 ($68.60) price objective on Stratec Biomedical AG and gave the stock a “neutral” rating in a research note on Monday, October 30th. Deutsche Bank AG set a €56.00 ($65.12) price objective on Stratec Biomedical AG and gave the stock a “neutral” rating in a research note on Tuesday, October 24th. Finally, Oddo Bhf set a €58.00 ($67.44) price objective on Stratec Biomedical AG and gave the stock a “neutral” rating in a research note on Monday, October 23rd.

COPYRIGHT VIOLATION NOTICE: “Stratec Biomedical AG (SBS) Given Average Rating of “Hold” by Brokerages” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/17/stratec-biomedical-ag-sbs-given-average-rating-of-hold-by-brokerages.html.

Stratec Biomedical AG (ETR:SBS) opened at €63.98 ($74.40) on Friday. Stratec Biomedical AG has a twelve month low of €41.30 ($48.02) and a twelve month high of €65.33 ($75.97).

About Stratec Biomedical AG

STRATEC Biomedical AG designs and manufactures solutions for automated processes in the fields of in vitro diagnostics and life sciences. The company operates through two segments, Instrumentation and All Other segments. It offers instrumentation products, such as automated analyzer systems, including THOLOS VMI-100, GEMINI, and GEMINI Combo for use in clinical diagnostics and biotechnology to laboratories, blood banks, and research institutes.

Analyst Recommendations for Stratec Biomedical AG (ETR:SBS)

Receive News & Stock Ratings for Stratec Biomedical AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stratec Biomedical AG and related stocks with our FREE daily email newsletter.